People
Kathryn Mims
Biography
Kathryn handles complex antitrust litigation—class actions, government enforcement, and merger challenges—and counsels clients through FTC, DOJ, and state attorney general investigations.
She helps pharmaceutical, healthcare, technology, energy, financial services, and consumer products clients navigate high-stakes antitrust matters, including class action defense, government enforcement actions and investigations, merger enforcement challenges, and the entire range of antitrust counseling, including on distribution pricing issues under the Robinson-Patman Act. Described by a client as "commercial, practical, and solution-oriented...truly a client's lawyer," Kathryn's work has delivered landmark results, including the first-ever full evidentiary record victory for a defendant in pharmaceutical "product hopping" litigation and guiding clients through multi-billion dollar merger challenges. Kathryn is a frequent author on a wide range of antitrust and competition issues and has been quoted in publications such as the Financial Times and Law360.
Practice areas
- Antitrust
- Antitrust litigation
- Corporate and commercial litigation
- Disputes
- White-collar defense and global investigations
Sectors
- Life sciences and healthcare
- Technology
- Energy
Selected experience
- Hikma Pharmaceuticals against "reverse payment" allegations relating to Jazz Pharmaceuticals' landmark drug, Xyrem.
- The National Association of REALTORS® coordinating defense of multiple antitrust litigations across the country.
- Avangrid in action challenging competitor’s tactics to delay major electricity project.
- Gerber in class action stemming from a Congressional report on presence of heavy metals in baby food.
- Avast on U.S. antitrust merger clearance for its USD9.2bn merger with Norton LifeLock.
- AbbVie against “reverse payment” allegations relating to drug Loestrin.
- Nestlé USA in action against hardware manufacturer to recover damages for anationwide cookie dough recall.
- Grupo Verzatec against antitrust challenges to a proposed merger.
- Pfizer in litigation challenging a competitor’s efforts to deter biologic competition.
- Anthem against the U.S. Department of Justice's lawsuit to block its USD54.2bn acquisition of Cigna Corporation, the largest merger ever in the health insurance industry at the time.
Education
- JD, University of Virginia School of Law, 2010
- BA, Tufts University, 2006
Admissions
- Admitted to the State of Virginia
- Admitted to the District of Columbia
- Admitted to the State of New York
- US Court of Appeals for the Second Circuit
- US Court of Appeals for the Third Circuit
- US Court of Appeals for the Fifth Circuit